Evidence map›Paper›PMID 34855302›Full record

ArticleFEBS open bio2022

Two steps are better than one: improving gene editing to treat cancer.

Francesca Minter

Open access · goldAbstract readComment
In one paragraph

Article in FEBS open bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Francesca MinterFEBS Open Bio Editorial Office, Cambridge, UK.
Open Geospatial Consortium · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene editing enables scientists to make precise changes to the genome of an organism using the cell's own ability to repair damaged DNA using a supplied DNA template. In recent years, gene editing has been applied clinically in the treatment of diseases such as cancer. Gene editing has been used in a type of immunotherapy, known as chimeric antigen receptor-expressing T cell (CAR-T) therapy, to restore the body's ability to find and kill specific cancer cells. For this therapy, viruses are often used to supply the cell with the DNA template used for creating the edit in the target DNA. However, the use of viruses in this context is laborious and costly. Developing non-viral methods for delivery of DNA templates for gene editing would circumvent these problems, but current methods can have toxic effects on cells and result in low editing efficiency. In a new article published in this issue, Yang et al. describe a novel method for viral-independent delivery of naked DNA and its incorporation into the genome for engineering cells for CAR-T therapy.

Indexed as

NeoplasmsReceptors, Chimeric AntigenGene EditingGenomeHumansImmunotherapyReceptors, Chimeric Antigen

Identifiers

PMID34855302
PMCPMC8727954
OpenAlexW3217084134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.